DALLAS, Texas China Aoxing Pharmaceutical acquiring the rights to phase II development-stage TJSL, and its potential $3 billion a year market.
In the article the author writes:
“China Aoxing Pharmaceutical Company Inc. (OTCBB: CAXG), the researcher, developer, maker and marketer of narcotic and pain-management drugs, recently announced it has acquired all rights to phase II development-stage TJSL, a new drug to treat primary dysmenorrhea (PD), or menstrual pain, in women.”
China Aoxing estimates a potential market of $3 billion each year in China for TJSL:
“Estimates of between 60% and 90% of women in China experience some level of PD, with approximately one-third of women there purchasing pain relief drugs regularly. The potential market for a successful trail completion of TJSL is estimated at $3 billion each year in China.”
No comments:
Post a Comment